Latest news with #medicalDevices
Associated Press
4 days ago
- Business
- Associated Press
Hologic Joins NEST Governance Committee to Advance the Use of Real-World Data in Medical Device Evaluation
ARLINGTON, Va.--(BUSINESS WIRE)--Jun 2, 2025-- The National Evaluation System for health Technology (NEST), an initiative of the Medical Device Innovation Consortium (MDIC), is pleased to welcome Hologic, a leading global medical device and diagnostic company, to its Governance Committee. This appointment reflects Hologic's commitment to advancing the use of real-world data (RWD) to support medical device evaluation and drive innovation in women's health. Hologic is the latest partner to join the NEST Governance Committee which convenes a diverse group of leaders from across the medical device ecosystem—including regulatory agencies, industry, academia, patient organizations, and health systems. NEST's mission aims to accelerate patient access to life-changing innovation by supporting the sustainable generation and use of timely, reliable and cost-effective real-world evidence (RWE) solutions throughout the medical device total product lifecycle. To advance this mission, NEST's Governance Committee plays a pivotal role by jointly identifying and prioritizing key initiatives that drive RWE generation for medical devices in support of regulatory submission packages, all while ensuring a patient-centered, inclusive, accountable, and transparent approach. 'Hologic is honored to join the NEST Governance Committee and contribute to advancing the use of real-world evidence in diagnostic and medical device evaluation,' said Jeff Hergesheimer, Senior Director, Regulatory Affairs at Hologic and newly appointed NEST Governance Committee member. 'Real-world data plays a critical role in accelerating innovation and improving patient outcomes. Through collaboration with NEST and other stakeholders, we look forward to driving solutions that enhance regulatory decisionmaking and deliver impactful healthcare advancements.' Through NEST Governance Committee involvement, Hologic will help accelerate patient access to cutting-edge technologies, bring a unique perspective as an industry leader in women's health, and contribute to the evolution of RWE approaches in regulatory decision making. Through its contributions, Hologic brings a valuable perspective grounded in both technical expertise and an enduring commitment to innovation in women's health. 'We are thrilled to welcome Hologic and Jeff to the NEST Governance Committee,' said Simon Mason, president at NEST. 'Their pioneering leadership in women's health meets an untapped need on our committee coupled with their commitment to employing RWE in regulatory submissions will bring invaluable insights and experience and most importantly, improve patient care and quality of life.' For more information about Hologic, visit About Hologic, Inc. Hologic, Inc. is a global leader in women's health dedicated to developing innovative medical technologies that effectively detect, diagnose and treat health conditions and raise the standard of care around the world. To learn more, visit and connect with us on LinkedIn,Facebook,X,Instagram and YouTube. About NEST (National Evaluation System for health Technology) In 2016, the U.S. Food and Drug Administration (FDA) awarded the Medical Device Innovation Consortium (MDIC) funding to establish the National Evaluation System for health Technology Coordinating Center (NEST). NEST is advancing the use of real-world evidence (RWE) in medical devices for regulatory decision-making and committed to transforming the way medical device technologies are tested, approved, and monitored. The Coordinating Center combines RWE system infrastructure with the unparalleled expertise of its network collaborators to accelerate patients' access to safe and effective medical technology and provide Quality Evidence by Design™. For more information on NEST, please visit or connect with us on LinkedIn. About MDIC (Medical Device Innovation Consortium) At MDIC, we unite in a shared mission to improve health and save lives by accelerating access to medical technologies. Through stakeholder collaboration, MDIC leads the way in advancing the scientific and technical foundations of medical device design, manufacturing, regulation, reimbursement and clinical integration. Founded in 2012 as a nonprofit, public-private partnership to elevate regulatory science, MDIC develops new approaches and tools for addressing shared challenges among medical device manufacturers, researchers, regulators, payers, patients, and health care providers. We deliver high impact work in the core areas of quality design and manufacturing, evidence generation, digital technology and transformation, and patient engagement. To learn more and join us in our mission, visit View source version on CONTACT: Media Contacts: Bridget Perry Sr. Director of Communications [email protected] Victoria Vice President, Brand and Experience MDIC [email protected] Investor Contact: Michael Watts Corporate Vice President, Investor Relations [email protected] KEYWORD: VIRGINIA UNITED STATES NORTH AMERICA INDUSTRY KEYWORD: OTHER HEALTH PROFESSIONAL SERVICES DATA MANAGEMENT TECHNOLOGY MEDICAL DEVICES HEALTH TECHNOLOGY DATA ANALYTICS SCIENCE MEDICAL SUPPLIES FDA OTHER TECHNOLOGY HEALTH OTHER SCIENCE SOURCE: Medical Device Innovation Consortium Copyright Business Wire 2025. PUB: 06/02/2025 11:03 AM/DISC: 06/02/2025 11:02 AM
South China Morning Post
4 days ago
- Business
- South China Morning Post
EU set to clamp down on China's access to medical device market as trade tensions simmer
European Union member states are expected to vote on Monday to restrict access to the bloc's vast procurement markets for Chinese medical device manufacturers in response to Beijing's refusal to open its own tenders to EU firms. It would mark the first use of the bloc's international procurement instrument (IPI) and comes after fruitless negotiations on market access with the Chinese government. Diplomatic sources said the vote was expected to pass, meaning the curbs could be implemented within weeks. The vote could add another layer of tension before the sides' trade chiefs meet on Tuesday. Maros Sefcovic and Wang Wentao were expected to see each other on the margins of an Organisation for Economic Cooperation and Development (OECD) ministerial conference in Paris, with a meeting slated for 4.30pm, EU sources said. 01:44 China's largest EV battery maker CATL celebrates strong debut at Hong Kong stock market China's largest EV battery maker CATL celebrates strong debut at Hong Kong stock market Sources said they were expected to attend a dinner gathering of 'influential' trade ministers organised by the World Trade Organization director general Ngozi Okonjo-Iweala. In January, a European Commission investigation concluded that there was 'clear evidence of China limiting access by EU medical device producers to its government contracts in an unfair and discriminatory way'. According to Brussels, Chinese medical device manufacturers have largely free access to public procurement tenders in the EU market, compared to the restrictions faced by European competitors in China. The EU probe singled out Beijing's 'Buy China' policies – particularly in the high-end segment of the medical device sector – as designed 'to directly favour domestic medical devices to the detriment of imported ones'. It noted that the devices were among the 10 designated under the Made in China 2025 programme, with targets for domestically produced products to account for half of all those used in county hospitals by 2020, 70 per cent by 2025 and 90 per cent by 2030.
Associated Press
22-05-2025
- Business
- Associated Press
Modular Medical to Participate in the Lytham Partners Spring 2025 Investor Conference on May 29, 2025
SAN DIEGO, CA / ACCESS Newswire / May 22, 2025 / Modular Medical, Inc. (NASDAQ:MODD) ('Modular Medical' or the 'Company'), an insulin delivery technology company with the first FDA-cleared patch pump designed specifically to target all adult 'almost-pumpers' with its user-friendly and affordable design, today announced it will participate in a webcast presentation and host one-on-one meetings with investors at the Lytham Partners Spring 2025 Investor Conference, taking place virtually, on Thursday, May 29, 2025. Company Webcast The webcast presentation will take place at 11:00 a.m. ET on Thursday, May 29, 2025. The webcast can be accessed by visiting the conference home page at or directly at The webcast will also be available for replay following the event. 1x1 Meetings Jeb Besser, the Company's Chief Executive Officer, will host virtual one-on-one meetings throughout the event. To arrange a meeting with Mr. Besser, please contact Lytham Partners at [email protected] or register for the event at About Modular Medical Modular Medical, Inc. (NASDAQ:MODD) is a medical device company that intends to launch the next generation of insulin delivery technology. Using its patented technologies, the Company seeks to eliminate the tradeoff between complexity and efficacy, thereby making top quality insulin delivery both affordable and simple to learn. Its mission is to improve access to the highest standard of glycemic control for people with diabetes taking it beyond 'superusers' and providing 'diabetes care for the rest of us.' Modular Medical was founded by Paul DiPerna, a seasoned medical device professional and microfluidics engineer. Prior to founding Modular Medical, Mr. DiPerna was the founder (in 2005) of Tandem Diabetes and invented and designed its t:slim insulin pump. More information is available at All trademarks mentioned herein are the property of their respective owners. CONTACT: Jeb Besser Chief Executive Officer Modular Medical, Inc. +1 (617) 399-1741 [email protected] SOURCE: Modular Medical, Inc. press release
Yahoo
20-05-2025
- Business
- Yahoo
Global Interventional Treatment Materials Market Trends, Growth Drivers and Future Outlook
Interventional Treatment Materials Market Outlook 2025-2034 Luton, Bedfordshire, United Kingdom, May 20, 2025 (GLOBE NEWSWIRE) -- Introduction The global interventional treatment materials market encompasses the medical devices and materials used in minimally invasive therapeutic procedures. These include essential tools such as catheters, stents, and guidewires, which enable doctors to perform interventions inside the body without open surgery. Over the past decade, there has been a marked shift in healthcare towards minimally invasive interventions due to their benefits in reducing patient trauma, shortening recovery times, and improving outcomes. This trend has fueled growth in the interventional materials market. In 2024, the global market size is estimated around $10.5 billion, and it is on track to expand steadily at a mid-single-digit annual growth rate. By 2034, the market is projected to reach approximately $18 billion, reflecting robust demand and continuous innovation in this field. This report provides a comprehensive analysis of the market's current state, recent developments, key players, and segment-wise insights (by product type, application, end user, technology, and distribution channel), along with forecasts through 2034. Get a Sample PDF Brochure: Market Overview The interventional treatment materials market is experiencing strong growth driven by a confluence of demographic and technological factors. An aging global population and the rising prevalence of chronic diseases are key growth drivers. As conditions like cardiovascular disease, diabetes, and cancer become more common, the need for effective, less invasive treatment options grows. Interventional procedures – such as angioplasty for heart disease or embolization for cancer – often rely on specialized catheters, guidewires, and stents, directly boosting demand for these materials. Additionally, ongoing technological advancements in medical devices are propelling the market forward. Innovations in material science (e.g. more flexible, biocompatible alloys and polymers) have led to next-generation products like drug-eluting stents, bioresorbable stents, and coated balloons that improve patient outcomes. The push toward minimally invasive surgery across medical disciplines has made these interventional tools indispensable in modern treatment protocols. Key Market Drivers and Trends Rising Chronic Disease Prevalence: The increasing incidence of cardiovascular diseases, cancers, and other chronic conditions worldwide is a fundamental driver. More patients with blocked arteries, tumors, or other conditions means a higher volume of interventions (like angioplasties or tumor embolizations) that require these materials. Shift to Minimally Invasive Procedures: Both patients and providers prefer less invasive treatments when available. The success of angioplasty/stenting over open-heart surgery, for example, exemplifies this shift. This drives demand for interventional devices (catheters, stents, guidewires) across cardiology, oncology, orthopedics, and beyond. Technological Innovation: Rapid advancements are improving device performance. Examples include drug-eluting and bioresorbable stents that reduce long-term complications, smart guidewires with better torque control, and catheters with improved coatings for navigation. New materials (like nitinol alloys for flexibility and shape memory) and designs are expanding the capabilities of interventional tools. Improved Imaging and Navigation: Better imaging techniques (high-resolution fluoroscopy, intravascular ultrasound, OCT, etc.) and navigation systems allow more complex procedures to be done interventionally. This in turn expands the scope of what can be treated with catheter-based approaches, indirectly boosting the market for the necessary materials. Growing Healthcare Investment: Many countries are increasing healthcare expenditures. There is a general trend of hospitals upgrading cath labs and interventional suites, especially in developing markets. As infrastructure improves, the volume of procedures (and thus material usage) rises. An expanding middle class in emerging economies is also driving demand for advanced treatments that utilize these devices. Challenges and Restraints High Device Costs: Advanced interventional devices can be expensive (for example, the latest generation drug-eluting stents or robotic catheter systems). In regions with constrained healthcare budgets or in low-resource hospitals, cost can be a barrier to adoption. Some providers may opt for older, cheaper alternatives or limit use to critical cases. Pricing Pressure and Competition: With many players in the market, competition is intense. Hospitals and purchasing groups often negotiate price reductions, which pressures manufacturers' profit margins. Companies must balance affordability with recouping R&D investments. Regulatory and Compliance Hurdles: Developing a new stent or catheter and getting it approved by regulators (like the FDA or CE marking in Europe) is a lengthy process. Strict safety and efficacy requirements are essential for patient safety but can delay time-to-market. Additionally, variations in regulatory standards across countries can complicate global product rollout. Supply Chain Vulnerabilities: The pandemic years highlighted issues in global supply chains for medical components. Shortages of certain plastics or metals, or delays in sterilization services, have impacted device availability at times. Ensuring a robust supply chain and redundancy is now a focus area for companies, but disruptions remain a risk. Clinical Adoption and Training: Some new technologies (e.g. robotic-assisted systems or novel imaging-guided techniques) have a learning curve. If physicians are not trained or comfortable with a new device, they may be slower to adopt it. Training programs and demonstrable improvements in outcomes are needed to convince practitioners to switch from established methods. Browse full Report - Market Segmentation by Product Type Stents – 45% of market share: Stents represent the largest product segment. They are vital in cardiovascular interventions, especially in treating coronary artery disease and peripheral arterial disease by propping open narrowed arteries. Their dominance is due to the high volume of cardiac procedures worldwide. In addition to vascular stents, this category includes stent grafts and other scaffolding implants used in gastroenterology or urology (e.g., bile duct stents, ureteral stents). Balloon Catheters – 25% of market share: Catheters are the second-largest segment, with balloon angioplasty catheters being a major subcategory (often counted separately because of their significance in opening blood vessels during angioplasty). Catheters are versatile tubes used across virtually all interventional procedures to deliver fluids, inflate balloons, deploy stents, or perform ablations. Guidewires – 20% of market share: Guidewires are the thin, flexible wires that physicians first insert and navigate through the anatomy, paving the way for catheters. While they account for a slightly smaller share of revenue relative to stents and catheters, guidewires are indispensable in almost every interventional procedure. They tend to be lower-cost per unit than stents, which partly explains their smaller share of the market value, but in terms of volume, they are used in huge numbers. Table: Global Market Share by Product Type (2024) Product Type Approx. Market Share (2024) Segment Characteristics & Outlook Stents 45% Largest segment driven by high-volume cardiovascular procedures; continual innovation in drug-eluting and bioresorbable stents will sustain growth. Balloon Catheters 25% Key tools for angioplasty and other interventions; new variants like drug-coated balloons boost utility and market demand. Guidewires 20% Ubiquitous support devices for navigation; advancements in materials (e.g. nitinol) improve performance and support steady growth. Others 10% (E.g. sheaths, coils, etc.) A collection of other interventional tools; growing with niche applications but relatively smaller share. Market Segmentation by Application Cardiology – 60% of market share: Cardiology (including interventional cardiology and endovascular procedures for peripheral vascular disease) is the largest application segment for interventional materials. The majority of catheters, guidewires, and stents produced globally are used in cardiovascular procedures. Oncology – 15% of market share: Oncology is an emerging and fast-growing application for interventional materials, often referred to as interventional oncology. This involves minimally invasive procedures to diagnose or treat cancers. Examples include tumor embolization (blocking blood supply to a tumor by injecting embolic agents via catheters), radioembolization (delivering radioactive microspheres through catheters to a tumor site, such as in liver cancer), and ablation procedures (using needle-like probes inserted percutaneously to destroy tumors with extreme heat, cold, or electric fields – some of these probes are guided by catheters or via similar techniques). Orthopedics – 10% of market share: Orthopedic applications of interventional materials are more limited in scope compared to cardiology or oncology, but they represent a growing niche. In orthopedics, 'interventional' procedures often mean minimally invasive treatments of bone or spine conditions. Table: Global Market Share by Application (2024) Application Area Approx. Share (2024) Notes on Usage and Growth Drivers Cardiology 60% Largest segment. Includes coronary and peripheral artery interventions; driven by widespread cardiovascular disease and established efficacy of stents and angioplasty. Oncology 15% Growing segment. Encompasses interventional oncology procedures (tumor embolization, ablation); fueled by rising cancer cases and adoption of minimally invasive tumor therapies. Orthopedics 10% Niche but expanding. Includes spinal interventions (e.g. kyphoplasty) and pain management; growth tied to aging populations and demand for non-surgical orthopedic treatments. Other Applications 15% (GI, Urology, Neuro, etc.) Various other uses of interventional materials; important in their fields (e.g. biliary stents, neurovascular coils) but individually smaller portions of the market. Market Segmentation by End User Hospitals – 60% of demand: Hospitals are the primary end users of interventional materials, accounting for roughly 60% of the market demand. This is because hospitals, especially large acute-care and specialty hospitals, perform the majority of complex interventional procedures. They have dedicated catheterization labs, interventional radiology suites, operating rooms, and the full range of support services (ICUs, emergency care) necessary for high-risk interventions. Ambulatory Surgical Centers (ASCs) – 30% of demand: ASCs are facilities that provide same-day surgical care, including diagnostic and preventive procedures, outside of a hospital setting. Over the last decade, many interventional procedures have started migrating to ASCs because of cost-effectiveness and efficiency. Clinics and Specialty Centers – 10% of demand: This segment includes smaller clinics, physician offices, or specialty centers that perform minimally invasive procedures. Table: Global Market Share by End User (2024) End User Approx. Usage Share (2024) Commentary Hospitals 60% Major tertiary hospitals perform the bulk of complex interventional procedures; they adopt new technologies quickly and drive most of the demand. Ambulatory Surgical Centers (ASCs) 30% ASCs handle many routine or moderate-risk interventions on an outpatient basis; their role is growing as healthcare shifts toward cost-effective same-day procedures. Clinics & Specialty Centers 10% Smaller clinics perform limited types of interventions (e.g. vein treatments, pain management); collectively a smaller share, with gradual growth as office-based labs increase. Market Segmentation by Technology Balloon Angioplasty Techniques: This refers to the classic technology of using balloon catheters to dilate vessels or spaces in the body. Balloon angioplasty is a cornerstone of interventional cardiology and is also used in other fields (like opening a narrowed bile duct or a peripheral artery). In terms of market impact, balloon angioplasty is extremely prevalent – a large proportion of interventional procedures involve a balloon catheter at some stage. Robotic-Assisted Interventions: Robotic-assisted technology in interventional procedures is an exciting and relatively new segment. Robotic catheter navigation systems (such as the CorPath system for vascular procedures or robotic systems for neurovascular and peripheral interventions) allow physicians to perform procedures with robotic precision and even remotely in some cases. Advanced Imaging-Guided Techniques: Imaging is an integral part of all interventional procedures – standard practice uses fluoroscopy (real-time X-ray) for guidance in vascular interventions, and ultrasound or CT for certain others. Here, we highlight the increasing use of advanced imaging techniques and image-guided adjuncts that are transforming interventions. This includes technologies like Intravascular Ultrasound (IVUS) and Optical Coherence Tomography (OCT), where miniaturized imaging probes (often on a catheter or guidewire) are used inside blood vessels to visualize plaques and stent deployment; fusion imaging that combines pre-op CT/MRI with live fluoroscopy for better guidance; and even augmented reality or 3D navigation systems for complex anatomy. Market Segmentation by Distribution Channel Direct Sales – 55% of market sales: In direct sales, medical device companies sell their products straight to hospitals, clinics, or healthcare systems without intermediaries. Over half of the global interventional materials market (by revenue) is supplied via direct sales. Major manufacturers (especially the large ones with global operations) maintain their own sales and distribution networks to serve big clients like hospital systems. Direct sales allow manufacturers to have closer relationships with physicians and hospitals, offer specialized training or support, and handle pricing and contracts directly. Distributors – 30% of market sales: Distributors are intermediary companies that purchase medical products from manufacturers and then supply them to healthcare providers. Roughly 30% of interventional materials reach end users through distributors. This channel is vital for covering geographically broad or hard-to-reach markets and for servicing smaller hospitals and clinics that may not have direct accounts with big manufacturers. Online and Other Channels – 15% of market sales: Though not explicitly listed in the segmentation request, it's worth noting the rise of online procurement platforms and other non-traditional channels, which currently account for roughly 15% of sales. Some hospitals use online marketplaces or centralized procurement systems to order medical supplies (including certain standard catheters or consumables). Table: Distribution Channels for Interventional Materials (Global, 2024) Distribution Channel Share of Sales (2024) Characteristics and Trends Direct Sales 55% Manufacturers selling directly to hospitals/ASCs; offers control over client relationships and often used for major accounts and advanced products. Distributors 30% Intermediaries that supply products to healthcare providers; crucial for broad market coverage and smaller facilities, especially in emerging markets or regions where manufacturers lack direct presence. Online/E-procurement 15% Web-based ordering platforms and group purchasing; growing in use for standard supplies, though high-touch device sales still rely on direct rep support. Buy Now - Key Players and Competitive Landscape Medtronic plc Boston Scientific Corporation Abbott Laboratories Johnson & Johnson (J&J) Terumo Corporation Cook Medical B. Braun Melsungen AG BD (Becton, Dickinson and Company) Philips Healthcare Stryker Corporation W. L. Gore & Associates (Gore Medical) Merit Medical Systems AngioDynamics, Inc. Asahi Intecc Co., Ltd. Recent Developments (2022–2025) Medtronic – October 2023: Product Launch – Medtronic launched a next-generation catheter-based interventional system aimed at enhancing minimally invasive surgeries. This new system integrates advanced imaging capabilities directly into the catheter platform, allowing surgeons to visualize and navigate with greater precision during procedures. The catheter also features improved maneuverability with a more responsive design. Boston Scientific – September 2023: Acquisition – Boston Scientific announced the acquisition of a promising startup specializing in next-generation interventional radiology tools. The startup's portfolio included advanced microcatheters and novel guidewire technology that utilize smart sensors for real-time feedback during procedures. Abbott Laboratories – August 2023: Regulatory Approval – Abbott received U.S. FDA approval for a new interventional device aimed at cardiovascular applications. The device – a novel drug-eluting scaffold (stent) – is notable for its enhanced drug delivery mechanism and a slimmer profile. Clinical trials demonstrated excellent efficacy in keeping arteries open with a favorable safety profile. Johnson & Johnson – June 2023: Strategic Partnership – Johnson & Johnson (through its medical device division) entered into a strategic partnership with a technology company specializing in artificial intelligence (AI) and machine learning for healthcare. The goal of the partnership is to integrate AI-driven analytics into interventional procedures. Concretely, they are working on software that can analyze live imaging feeds and patient data during an intervention to provide decision support – for example, suggesting optimal catheter paths, detecting subtle changes in blood flow, or predicting complications. By combining J&J's medical expertise with the tech company's AI algorithms, the collaboration aims to create smarter interventional systems that help physicians plan and execute procedures with enhanced precision. Stryker Corporation – May 2023: Expansion Initiative – Stryker announced the expansion of one of its manufacturing facilities in India to increase production capacity for interventional treatment materials. This expansion is in response to growing demand in the Asia-Pacific region for interventional products, including Stryker's neurovascular stents and catheters. By scaling up production in India, Stryker aims to serve regional markets more efficiently, reduce costs, and mitigate supply chain risks. Johnson & Johnson – November 2022: Major Acquisition – In late 2022, J&J made headlines by acquiring Abiomed, a company well-known for its Impella heart pump devices, in a multi-billion dollar deal. While Abiomed's products (percutaneous heart pumps) are somewhat adjacent to the classic 'catheter, stent, guidewire' trio, they are used in interventional cardiology for supporting patients with severe heart failure or during high-risk angioplasty. This acquisition by J&J signaled the company's re-entrance into frontline interventional cardiology devices in a big way. Market Recovery Post-Pandemic (2022–2023): After the COVID-19 pandemic disruptions of 2020-2021, the years 2022 and 2023 saw a robust recovery in elective interventional procedure volumes. Hospitals that had postponed non-urgent cardiovascular and other interventions caught up with backlog, which led to a surge in demand for stents, catheters, and related supplies. Companies reported improved sales, especially in the second half of 2022, as cath labs returned to near-full operation. Technology Integration and Minor Players (2024): As we moved into 2024, there's an ongoing wave of integration of digital technology in interventional products. Smaller companies and startups introduced innovations like catheters with built-in sensors that can provide data on pressure or blood flow from within vessels, and guidewires that can act as imaging tools (combining guidance and diagnostics). This report is also available in the following languages : Japanese (介入治療材料市場), Korean (중재 치료 재료 시장), Chinese (介入治疗材料市场), French (Marché des matériaux de traitement interventionnel), German (Markt für interventionelle Behandlungsmaterialien), and Italian (Mercato dei materiali per il trattamento interventistico), etc. Download Full PDF Sample Copy of Market Report @ Related reports - New Medical Dressings Market The global new medical dressings market is valued at an estimated $8.5 billion in 2024, reflecting a steady demand driven by advancements in wound care technologies and an increasing prevalence of chronic wounds. The market is projected to reach approximately $14 billion by 2034, showcasing significant growth opportunities over the next decade. Drug Dispensing Robot Market The global drug dispensing robot market is valued at approximately $3.2 billion in 2024 and is anticipated to reach $7.5 billion by 2034, reflecting a robust Compound Annual Growth Rate (CAGR) of around 9.1% during the forecast period from 2025 to 2034. Digital All-In-One Operating Room System Market The global digital all-in-one operating room system market is poised for significant growth, with an estimated market value of $4.5 billion in 2024. This market is projected to reach approximately $10.8 billion by 2034, reflecting a robust Compound Annual Growth Rate (CAGR) of 9.1% during the forecast period from 2025 to 2034. Single Use Transfusion Sets Market The global single-use transfusion sets market is valued at approximately $2.5 billion in 2024, with expectations to reach around $4.2 billion by 2034. This growth reflects a robust Compound Annual Growth Rate (CAGR) of 5.4% during the forecast period from 2025 to 2034. Regenerative Dermal Fillers Market The global regenerative dermal fillers market is valued at approximately $6.3 billion in 2024 and is projected to reach around $10.5 billion by 2034, reflecting robust growth opportunities within the sector. This forecast indicates a Compound Annual Growth Rate (CAGR) of about 5.2% from 2025 to 2034. Photonic Medical Equipment Market The global photonic medical equipment market is valued at approximately $15.4 billion in 2024, driven by advancements in laser and imaging technologies that enhance diagnostic and therapeutic capabilities. The market is anticipated to reach around $38 billion by 2034, reflecting significant growth opportunities as the healthcare sector increasingly adopts minimally invasive procedures. This translates to a robust Compound Annual Growth Rate (CAGR) of approximately 9.2% during the forecast period from 2025 to 2034. Freezing Fat Reduction Apparatus Market The global freezing fat reduction apparatus market is projected to reach a value of approximately $800 million in 2024, reflecting a robust demand driven by rising interest in non-invasive body contouring procedures. The market is expected to experience substantial growth, with a forecasted value of around $1.6 billion by 2034, representing a Compound Annual Growth Rate (CAGR) of about 7.5% during the period from 2025 to 2034. Intelligent Blood Collection Management System Market The global Intelligent Blood Collection Management System (IBCMS) market is valued at approximately $2.5 billion in 2024, with projections suggesting a robust growth trajectory that could elevate its value to around $5 billion by 2034. This growth reflects a Compound Annual Growth Rate (CAGR) of approximately 8% during the forecast period from 2025 to 2034. Negative Pressure Diverter Market The global negative pressure diverter market is valued at approximately $3 billion in 2024. As healthcare facilities prioritize infection control and patient safety, the market is poised for robust growth. The projected market value for the period 2025–2034 is estimated to reach around $5 billion, reflecting a Compound Annual Growth Rate (CAGR) of approximately 6.2%. Medical CT Film Market The global medical CT film market is poised for robust growth, valued at approximately $1.2 billion in 2024. This sector is projected to expand at a CAGR of 6.5% from 2025 to 2034, reaching an estimated market value of around $2.3 billion by the end of the forecast period. 3A Sanitary Fixtures for Pharma & Biotech Market The global 3A sanitary fixtures market for the pharmaceutical and biotech sectors is valued at approximately $3.2 billion in 2024, with projections indicating a robust expansion, reaching an estimated $5.6 billion by 2034. This growth reflects a Compound Annual Growth Rate (CAGR) of around 6.2% during the 2025-2034 forecast period. Shielded Isolators and Hot Cells Market The global shielded isolators and hot cells market is valued at approximately $1.2 billion in 2024, with expectations to reach around $2.4 billion by 2034. This growth reflects a robust Compound Annual Growth Rate (CAGR) of 7.4% during the forecast period from 2025 to 2034. Bifidus Product Market The global bifidus product market is estimated to reach approximately $1.3 billion in 2024, driven by increasing health consciousness and the rising demand for probiotic-rich foods. The market is projected to grow at a compound annual growth rate (CAGR) of 8.4%, reaching an estimated value of $2.7 billion by 2034. Molecular Diagnostic Kits Market The global molecular diagnostic kits market is valued at approximately $9.3 billion in 2024, reflecting significant advancements in biotechnology and increasing demand for rapid and accurate diagnostics. The market is projected to reach around $15.6 billion by 2034, driven by heightened adoption of personalized medicine and growing prevalence of infectious diseases. The Compound Annual Growth Rate (CAGR) for the forecast period from 2025 to 2034 is estimated at 6.0%. Medical Reusable Sterilization Container Market The global market for medical reusable sterilization containers is projected to be valued at approximately $1.2 billion in 2024. This market is expected to experience substantial growth, with a projected value of around $2.3 billion by 2034. The Compound Annual Growth Rate (CAGR) for the forecast period from 2025 to 2034 is estimated at 7.1%. Ventilator Humidifiers Market The global ventilator humidifiers market is projected to reach a value of approximately $1.2 billion in 2024, driven by increasing demand for respiratory care across healthcare facilities. The market is expected to grow significantly, with an estimated value of $2.5 billion by 2034, corresponding to a robust Compound Annual Growth Rate (CAGR) of around 8.5% during the forecast period from 2025 to 2034. Prefilled Humidifiers Market the global market for prefilled humidifiers is valued at approximately $2.1 billion, driven by rising consumer demand for healthier indoor air quality and growing awareness of respiratory ailments. The market is projected to expand significantly, with an estimated value of $3.8 billion by 2034, reflecting a robust Compound Annual Growth Rate (CAGR) of 6.2% during the forecast period from 2025 to 2034. Prefilled Bubble Humidifiers Market The global prefilled bubble humidifier market is projected to reach a value of approximately $1.2 billion in 2024, driven by an increasing prevalence of respiratory diseases and the growing need for effective humidification in medical settings. The market is expected to experience significant growth, with a projected value of around $2.5 billion by 2034 BPDA Market The global Business Process Digital Automation (BPDA) market is poised for substantial growth, with an estimated value of approximately $6.5 billion in 2024. This momentum is expected to continue, leading to a projected market value of around $15 billion by 2034. This growth corresponds to a robust Compound Annual Growth Rate (CAGR) of approximately 9% over the forecast period from 2025 to 2034. Near Infrared Medical Fluorescence Imaging System Market The global near-infrared (NIR) medical fluorescence imaging system market is valued at approximately $1.3 billion in 2024. It is projected to reach around $3.1 billion by 2034, reflecting significant growth driven by advancements in imaging technology, increasing adoption of NIR imaging in surgical procedures, and the rising prevalence of cancer and other diseases that necessitate precise imaging techniques. The market is expected to grow at a compound annual growth rate (CAGR) of 9% during the forecast period from 2025 to 2034. CONTACT: Contact Data Irfan Tamboli (Head of Sales) Phone: + 1704 266 3234 Email: sales@ in to access your portfolio
